34. Neurofibromatosis Clinical trials / Disease details
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194999 | 15/10/2019 | 14/10/2019 | BeatNF2 trial | A Randomized Double-blind Multicenter trial to Assess the Efficacy and Safety of Bevacizumab for Neurofibromatosis Type 2 | Neurofibromatosis type 2 | Intervention name : Bevacizumab (Genitical Recombination) INN of the intervention : Bevacizumab (Genitical Recombination) Dosage And administration of the intervention : 5mg/kg in a total volume of 100ml, div, every 2 week Control intervention name : Isotonic sodium chloride solution INN of the control intervention : - Dosage And administration of the control intervention : 100ml, div | Kiyoshi Saito | Masazumi Fujii, Masao Kobayakawa, Akihiro Inano, Jun Sakuma, Taku Sato, Akio Morita, Mitsuhiro Hasegawa, Takafumi Mitsuhara, Takashi Tamiya, Takeo Goro, Shigeru Yamaguchi, Hirofumi Nakatomi, Soichi Oya | pending | 18 | 64 | BOTH | 60 | Phase 2 | Japan |